💥🇺🇸#VRTX Vertex Pharmaceuticals stock price target raised to $305 from $281 at J.P. Morgan💥🇺🇸#SGEN Seattle Genetics stock price target raised to $179 from $150 at J.P. Morgan💥🇺🇸#LRCX Lam Research stock price target raised to $435 from $270 at B. Riley FBR⚠️🇺🇸#BIIB Biogen stock price target cut to $272 from $293 at J.P. Morgan💥🇺🇸#PYPD POLYPID started at OUTPERFORM with $23 stock price target at Raymond James💥🇺🇸#EXK ENDEAVOUR SILVER started at BUY with $4.75 stock price target at B. Riley FBR⚠️🇺🇸#FNHC FEDNAT downgraded to OUTPERFORM from STRONG BUY at Raymond James⚠️🇺🇸#NDAQ NASDAQ downgraded to MARKET PERFORM from OUTPERFORM at Raymond James
Акции США
BIIB
Biogen сокращает целевую цену акций до $272
Biogen снижает свою целевую цену акций до $272, согласно J.P. Morgan.
Контекст по активу
Biogen Inc. (BIIB). Бумага относится к сектору "Здравоохранение". Последняя цена: 216,17 USD. Текущая дневная динамика: 0%. Актив есть в портфелях 34 пользователей FinPlan. Капитализация около 31,75 млрд USD.